peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

IGF analog

IGF-1 LR3

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

In this study, IGF-1 LR3 (Insulin-like Growth Factor Long Arginine 3) was incorporated into a GelMA-integrated, decellularized plant-based nerve conduit as a controlled-release payload.

Sources[1]pubmedRevolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.This study introduces the first-ever decellularized plant-based nerve conduit, fabricated from Alstroemeria stem material, integrated with GelMA, and featuring controlled release of Insulin-like Growth Factor Long Arginine 3 (IGF-1 LR3) for enhanced axonal regeneration.
Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This study introduces the first-ever decellularized plant-based nerve conduit, fabricated from Alstroemeria stem material, integrated with GelMA, and featuring controlled release of Insulin-like Growth Factor Long Arginine 3 (IGF-1 LR3) for enhanced axonal regeneration.”

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. · Abstract

    pubmed:41015370:05e65dac2a76:05e65dac2a76

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

In a rat sciatic nerve defect model, an IGF-1 LR3 controlled-release decellularized conduit was reported to significantly improve axonal regeneration.

Sources[1]pubmedRevolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.The IGF-1 LR3-controlled releasing decellularized conduit significantly improved axonal regeneration
Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The IGF-1 LR3-controlled releasing decellularized conduit significantly improved axonal regeneration”

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. · Abstract

    pubmed:41015370:05e65dac2a76:05e65dac2a76

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
  • 10 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (4), assurance_score_below_0.72 (4), current_regulatory_source_required (3), extraction_ambiguity (8), high_risk_requires_regulatory_or_two_independent_sources (6), no_direct_support (8), proposal_not_staged (1)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. ↗

    pubmed · published 2025-11-01 · retrieved 2026-08-27T11:48:55Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-27T11:48:55Z

0d17b17d812da7f05957df45a9205ca32446b72bd3dd824dee1416b77788738f